BERLIN (Reuters) – Shares in Germany’s BioNTech fell on Monday after it flagged write-downs of up to 900 million euros ($947 million) reflecting similar charges its partner Pfizer announced on their COVID-19 vaccine business last week.
Hit by a plunge in use of pandemic-related products, Pfizer on Friday said it would take $900 million in write-offs and other charges for their jointly developed Comirnaty vaccine, on top of much larger write-offs on Pfizer’s own COVID treatment Paxlovid.
For its third-quarter accounts, BioNTech will likely “recognise the effect of Pfizer’s inventory write-offs and other charges related to Comirnaty in the third quarter of 2023 up to 0.9 billion euros, which represents BioNTech’s half of the gross profit-sharing agreement with Pfizer,” it said in a statement.
Shares in the vaccine maker, which is also developing cancer treatments, were down 7% to a two-month low in Frankfurt as of 0756 GMT.
BioNTech, which relies on vaccine-related profit-sharing payments from its U.S. partner for much of its revenue, said the write-offs would also reduce its 2023 revenue.
A BioNTech spokesperson on Monday declined to comment on the company’s current 2023 outlook, which is for COVID-19 vaccine revenue of about 5 billion euros.
Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!
By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
The company is scheduled to release detailed third-quarter figures on Nov. 6.
The company added that it had been told by Pfizer that most of the write-offs relate to raw materials, as well as to inventories of vaccine versions that are older than the upgraded one currently in use.
($1 = 0.9498 euros)
(Reporting by Ludwig Burger and Rachel More; editing by Miranda Murray and Jason Neely)
Uma Rajagopal has been managing the posting of content for multiple platforms since 2021, including Global Banking & Finance Review, Asset Digest, Biz Dispatch, Blockchain Tribune, Business Express, Brands Journal, Companies Digest, Economy Standard, Entrepreneur Tribune, Finance Digest, Fintech Herald, Global Islamic Finance Magazine, International Releases, Online World News, Luxury Adviser, Palmbay Herald, Startup Observer, Technology Dispatch, Trading Herald, and Wealth Tribune. Her role ensures that content is published accurately and efficiently across these diverse publications.
